Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, shared data from its AL003 and AL101 programs in poster presentations at the 14th Clinical Trials on Alzheimer's Disease (CTA...
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector, will participate in a fireside chat at ...
Alector (NASDAQ:ALEC): Q3 GAAP EPS of $1.49 misses by $1.49. Revenue of $182.41M (+2991.7% Y/Y) misses by $116.26M. Press Release For further details see: Alector EPS misses by $1.49, misses on revenue
Initiated Phase 2 Clinical Trial of AL001 for the Treatment of Amyotrophic Lateral Sclerosis Executed a Global Collaboration with GSK to Co-development and Co-commercialize Alector’s Progranulin Franchise Molecules for the Treatment of a Range of Neurodegenerative Disease...
Company to Host Analyst and Investor Conference Call on November 12 at 4:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations at ...
Alector develops immunology targets for neurodegenerative diseases. It recently signed up for a $2.2bn deal with GSK. Early stage positive data makes it very attractive. For further details see: Alector: The GSK Deal Is A Major Value Add
Cyclerion is a spinoff from Ironwood Pharmaceuticals that has had 2 clinical failures but has a unique lead asset in neurodegeneration. Cyclerion has upcoming phase 2 data coming out in H12022 that will be a major inflection point to potentially open up new opportunities for the distr...
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the addition of Elizabeth (Betsy) A. Garofalo, M.D., to the Company’s Board of Directors. Dr. Garofal...
Randomized, placebo-controlled Phase 2 trial will enroll patients with C9orf72-associated ALS SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that...
The packaged-foods sector provided a ray of light for investors on Wednesday despite a slide for the overall markets. The segment bounced back from recent weakness on signs that companies might be starting to catch up to the inflation pressures that have weighed on the group. General Mil...
News, Short Squeeze, Breakout and More Instantly...
--INVOKE-2 is the first global Phas e 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative stud...
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Associatio...
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5 th Annual Neuro Pers...